在帕洛西斯马夜间血红蛋白尿症中使用佩格塞塔科普兰的现实世界经验
Morag Griffin1, Richard Kelly1, Isabelle Brindel2
1PNH Service, St James University Hospital, Leeds, UK.
American journal of hematology
|February 13, 2024
概括
佩格塞塔科普兰有效地用外血管血解 (EVH) 治疗阴性夜间血红蛋白尿症 (PNH),改善实际使用中的血红蛋白水平. 突破性血液溶解事件可以通过及时干预来管理,确保大多数患者的持续治疗.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 阴性夜间血红蛋白尿 (PNH) 是一种罕见的血液疾病.
- 血管外血液溶解 (EVH) 是PNH患者治疗C5抑制剂 (如eculizumab) 的并发症.
- 佩格塞塔科普兰为患有EVH的PNH提供了向治疗的选择.
研究的目的:
- 评估 pegcetacoplan 在 PNH 患有 EVH 的患者的实际有效性和安全性.
- 评估治疗结果,包括血红蛋白水平,网细胞计数和乳酸脱酶 (LDH) 水平.
- 记录突破性血液溶解 (BTH) 事件的发生和管理.
主要方法:
- 在英国和法国 (2019-2023) 接受佩格塞塔科普兰的48名患者的回顾性分析.
- 包括以前接受过C5抑制剂治疗的患者,包括PEGASUS临床试验中的患者.
- 收集关于佩格塞塔科普兰持续时间,输血史,血液学参数和BTH事件的数据.
主要成果:
- 经过3个月的Pegcetacoplan治疗,平均血红蛋白增加了22.3g/L,并减少了网细胞数量.
- 平均LDH水平保持不变,表明持续的疾病控制.
- 突破性血液溶解事件发生在13/48名患者中,但通过剂量修改可以控制,大多数患者继续治疗.
结论:
- 在现实环境中,Pegcetacoplan有效地改善了EPH的PNH患者的血液学参数.
- 治疗通常耐受良好,可控的BTH事件.
- 佩格塞塔科普兰代表了PNH患者在C5抑制剂上经历EVH的有价值的治疗选择.
相关概念视频
02:45Blood Transfusion and Agglutination
13.0K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
13.0K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97